Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0005684 (
bladder cancer
)
16,431
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
188
Rhenium-hydroxyethylidene-1,1-diphosphonate (
188
Re-
HEDP
) is a clinically established radiopharmaceutical for bone pain palliation of patients with metastatic bone cancer. Herein, the effectiveness of
188
Re-
HEDP
for the palliation of painful bone metastases was investigated in an uncontrolled initial trial in 48 patients with different types of advanced cancers. A group of 48 patients with painful bone metastases of lung, prostate, breast, renal, and
bladder cancer
was treated with 2.96-4.44 GBq of
188
Re-
HEDP
. The overall response rate in this group of patients was 89.5%, and their mean visual analog scale score showed a reduction from 9.1 to 5.3 (
P
< 0.003) after 1 week posttherapy. The patients did not report serious adverse effects either during intravenous administration or within 24 h postadministration of
188
Re-
HEDP
. Flare reaction was observed in 54.2% of patients between day 1 and day 3. There was no correlation between flare reaction and response to therapy (
P
< 0.05). Although bone marrow suppression was observed in patients receiving higher doses of
188
Re-
HEDP
, it did not result in any significant clinical problems. The present study confirmed the clinical utility and cost-effectiveness of
188
Re-
HEDP
for palliation of painful bone metastases from various types of cancer in developing countries.
...
PMID:Clinical utility of
188
Rhenium-hydroxyethylidene-1,1-diphosphonate as a bone pain palliative in multiple malignancies. 3050 19
